Cosmo Pharmaceuticals N.V. (SWX:COPN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
100.60
-0.40 (-0.40%)
At close: Dec 19, 2025
70.51%
Market Cap1.60B
Revenue (ttm)170.24M
Net Income (ttm)56.03M
Shares Out15.94M
EPS (ttm)3.43
PE Ratio29.36
Forward PE368.90
Dividend1.91 (1.90%)
Ex-Dividend DateJun 4, 2025
Volume55,062
Average Volume103,631
Open101.00
Previous Close101.00
Day's Range99.90 - 101.80
52-Week Range41.60 - 108.00
Beta1.28
RSI74.89
Earnings DateMar 6, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive... [Read more]

Sector Healthcare
Founded 1997
Employees 322
Stock Exchange SIX Swiss Exchange
Ticker Symbol COPN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Is this the end of baldness? This stock jumps 50% on breakthrough

Cosmo Pharmaceuticals (SWX: COPN) has rallied more than 50% over the past week, driven by positive results in late-stage trials … Continue reading The post Is this the end of baldness? This stock jump...

12 days ago - Finbold

Cosmo Pharmaceuticals (CMOPF) Stock Soars on Promising Hair Loss Treatment Results

Cosmo Pharmaceuticals (CMOPF) Stock Soars on Promising Hair Loss Treatment Results

17 days ago - GuruFocus

EU Grants Marketing Authorization For Winlevi Cream

(RTTNews) - Cosmo Pharmaceuticals (COPN.SW) and Glenmark Pharmaceuticals (53229) announced on Monday that they have gained approval from the European Commission for Winlevi, which is a clascoterone cr...

19 days ago - Nasdaq

EU Approves Cosmo Pharma' Winlevi For Acne Treatment In Adults And Adolescents

(RTTNews) - Cosmo Pharmaceuticals N.V. (COPN.SW) announced that the European Commission has granted regulatory approval for Winlevi (clascoterone 1% cream) in the European Union. The topical treatment...

2 months ago - Nasdaq

Winlevi Acne Cream Secures EU Drug Panel Support in Reversal for Cosmo

Cosmo Pharmaceuticals NV won the backing of European Union regulators for its acne treatment cream, Winlevi, after a surprise initial rejection earlier this year.

4 months ago - Financial Post

Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel

Biopharma - Der Pharmakonzern Cosmo Pharmaceuticals hat Federico Sommariva zum neuen Chief Legal Counsel ernannt.

9 months ago - Cash

Cosmo Pharmaceuticals reports FY results

9 months ago - Seeking Alpha

Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...

Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and Strategic Challenges

10 months ago - GuruFocus

Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript

Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript

10 months ago - GuruFocus

Cosmo Pharmaceuticals gets new finance chief

Cosmo Pharmaceuticals N.V. appoints Svetlana Sigalova as new CFO, succeeding Niall Donnelly effective November 11, 2024.

1 year ago - Seeking Alpha